PRODUCT DESCRIPTION:

Conjugated Estrogen 0.625 MG Tablets are formulated to relieve symptoms of estrogen deficiency in postmenopausal women. Extracted from a blend of naturally occurring estrogens, these tablets offer proven effectiveness in managing moderate to severe menopausal symptoms, preventing postmenopausal osteoporosis, and supporting hormonal balance in women with ovarian failure or after oophorectomy.

This formulation is a gold-standard therapy in hormone replacement regimens, helping restore physiological estrogen levels for enhanced quality of life in women during and after menopause.

Formulation & Presentation:

• Dosage Form: Tablets
• Presentation: Available in Blister Pack or HDPE Bottle (As per market requirement)
• Available Strengths: Cyproterone Acetate 50 MG Table Conjugated Estrogen 0.625 MG
• Route of Administration: Oral (As per physician’s discretion or therapeutic indication)

Therapeutic Indications:

• Management of vasomotor symptoms associated with menopause (e.g., hot flashes, night sweats)
• Treatment of vulvar and vaginal atrophy due to estrogen deficiency
• Prevention of postmenopausal osteoporosis
• Estrogen replacement in women with primary ovarian insufficiency or post-oophorectomy
• Palliative treatment of advanced androgen-dependent prostate and breast cancer (off-label)

Side Effects:

• COMMON:  Management of vasomotor symptoms associated with menopause (e.g., hot flashes, night sweats), Treatment of vulvar and vaginal atrophy due to estrogen deficiency, Prevention of postmenopausal osteoporosis, Estrogen replacement in women with primary ovarian insufficiency or post-oophorectomy, Palliative treatment of advanced androgen-dependent prostate and breast cancer (off-label)
• SERIOUS (RARE): Venous thromboembolism (VTE), Endometrial hyperplasia or carcinoma (with unopposed use), Stroke or myocardial infarction, Liver dysfunction, Visual disturbances
• PRECAUTIONS: Contraindicated in women with known or suspected breast cancer, active thromboembolic disease, or unexplained vaginal bleeding
  • Not recommended during pregnancy or breastfeeding
  • Use with caution in patients with liver disease, asthma, epilepsy, or cardiovascular conditions
  • When used in women with an intact uterus, co-administration with progestin is recommended to reduce the risk of endometrial cancer
  • Regular evaluation of risks and benefits is essential during long-term therapy